Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming

• Published in: Frontiers in immunology 2019-04, Vol.10, p.730-730
• Main Authors: Yusuf, Yenni, Yoshii, Tatsuya, Iyori, Mitsuhiro, Yoshida, Kunitaka, Mizukami, Hiroaki, Fukumoto, Shinya, Yamamoto, Daisuke S, Alam, Asrar, Emran, Talha Bin, Amelia, Fitri, Islam, Ashekul, Otsuka, Hiromu, Takashima, Eizo, Tsuboi, Takafumi, Yoshida, Shigeto
• Format: Article
• Language: English
• Subjects: adeno-associated virus; human adenovirus serotype 5; Immunology; malaria vaccine; Pfs25; Plasmodium falciparum circumsporozoite protein; transmission-blocking
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.00730

An ideal malaria vaccine platform should potently induce protective immune responses and block parasite transmission from mosquito to human, and it should maintain these effects for an extended period. Here, we have focused on vaccine development based on adeno-associated virus serotype 1 (AAV1), a viral vector widely studied in the field of clinical gene therapy that is able to induce long-term transgene expression without causing toxicity . Our results show the potential utility of AAV1 vectors as an extremely potent booster vaccine to induce durable immunity when combined with an adenovirus-priming vaccine in a rodent malaria model. We generated a series of recombinant AAV1s and human adenovirus type 5 (AdHu5) expressing either circumsporozoite protein (PfCSP) or P25 (Pfs25) protein. Heterologous two-dose immunization with an AdHu5-prime and AAV1-boost (AdHu5-AAV1) elicited robust and durable PfCSP- or Pfs25-specific functional antibodies over 280 days. Regarding protective efficacy, AdHu5-AAV1 PfCSP achieved high sterile protection (up to 80% protection rate) against challenge with transgenic sporozoites expressing PfCSP. When examining transmission-blocking (TB) efficacy, we found that immunization with AdHu5-AAV1 Pfs25 maintained TB activity against transgenic expressing Pfs25 for 287 days (99% reduction in oocyst intensity, 85% reduction in oocyst prevalence). Our data indicate that AAV1-based malaria vaccines can confer potent and durable protection as well as TB efficacy when administered following an AdHu5 priming vaccine, supporting the further evaluation of this regimen in clinical trials as a next-generation malaria vaccine platform.